Medindia

X

Circulating Tumor Cells Industry to Reach $17.96 billion with 19.2% CAGR by 2022

Thursday, June 9, 2016 Cancer News J E 4
Advertisement
Wiseguyreports.com add report on "Circulating Tumor Cells - Global Market Outlook (2015-2022)" new report to its research database. The report spread across 132 pages with table and figures.

PUNE, India, June 8, 2016 /PRNewswire-iReach/ -- The Global Circulating Tumor Cells Market is accounted for $4.41 billion in 2015 and is expected to reach $17.96 billion by 2022 growing at a CAGR of 19.2 % from 2015 to 2022. The rising demand for high Benefit-Cost Ratio (BCR) associated with CTCs prognostic technology is the major factor boosting the market growth. Furthermore, advancements in biomedical imaging and bioengineering technology are some of the key factors driving the market. However, high cost associated with the diagnosing and reluctance among people towards adopting highly developed prognostic technologies inhibit the market growth. The recent trends in global Circulating Tumor Cells are strengthening distribution network of CTCs prognostic technologies in emerging economies and the technical advancement of CTCs-based customized medicines.

Photo - http://photos.prnewswire.com/prnh/20160608/376871LOGO

Get Complete Report Details @ https://www.wiseguyreports.com/reports/circulating-tumor-cells-global-market-outlook-2015.

Tumor cell detection is the foremost product segment primarily due to the advantages related with therapeutic monitoring and high procedure prices. North America region is expected to witness highest growth rate during the forecast period due to increasing demand in number of research projects. In addition, the U.S. Government also supports research by funding various institutes, which grant research funds.

Some of the key players in the market include Adnagen AG, Advanced Cell Diagnostics, Apocell, Aviva Biosciences, Biocep Ltd., Biocept Inc., Biofluidica, Canopus Biosciences, CellTraffix Inc., Clearbridge BioMedics, Creatv Microtech Inc., Cynvenio Biosystems Inc. , Epic Biosciences, Fluxion Biosciences., Greiner Bio-One GmbH, Ikonisys Inc., IV Diagnostics Inc., Janssen Diagnostics, Miltenyi Biotech and Nanostring Technologies Inc.

Purchase a 1-User License Copy @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=456579.

Technologies Covered: 

  • Tumor Cell Enrichment 
    • Filtration 
    • Centrifugation 
    • Immunological and Immunomagnetic 
  • Tumor Cell Detection 
    • Molecular 
    • Optical

Applications Covered: 

  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Other Applications

The report offers:

- Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements

Inquire more about this report@ https://www.wiseguyreports.com/enquiry/circulating-tumor-cells-global-market-outlook-2015.

Contact for More Information at sales@wiseguyreports.com or +1 (646) 845 9349 (US) and +44 208 133 9349 (UK)

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. We also provide COTS (Commercial off the Shelf) business sector reports as custom exploration agreeing your particular needs.

Media Contact: Norah Trent, WiseGuy Reports, +1 646 845 9349, sales@wiseguyreports.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE WiseGuy Reports

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
First Patient in Ohio Treated with Non-Invasive HI...
S
Non-Small Cell Lung Cancer Therapeutics in Asia-Pa...